277 related articles for article (PubMed ID: 22891351)
1. STAT3 negatively regulates thyroid tumorigenesis.
Couto JP; Daly L; Almeida A; Knauf JA; Fagin JA; Sobrinho-Simões M; Lima J; Máximo V; Soares P; Lyden D; Bromberg JF
Proc Natl Acad Sci U S A; 2012 Aug; 109(35):E2361-70. PubMed ID: 22891351
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC).
Kim DW; Chung HK; Park KC; Hwang JH; Jo YS; Chung J; Kalvakolanu DV; Resta N; Shong M
Mol Endocrinol; 2007 Dec; 21(12):3039-49. PubMed ID: 17761947
[TBL] [Abstract][Full Text] [Related]
3. Curcumin-Mediated Apoptotic Cell Death in Papillary Thyroid Cancer and Cancer Stem-Like Cells through Targeting of the JAK/STAT3 Signaling Pathway.
Khan AQ; Ahmed EI; Elareer N; Fathima H; Prabhu KS; Siveen KS; Kulinski M; Azizi F; Dermime S; Ahmad A; Steinhoff M; Uddin S
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936675
[TBL] [Abstract][Full Text] [Related]
4. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
5. Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation.
Hwang JH; Kim DW; Suh JM; Kim H; Song JH; Hwang ES; Park KC; Chung HK; Kim JM; Lee TH; Yu DY; Shong M
Mol Endocrinol; 2003 Jun; 17(6):1155-66. PubMed ID: 12637586
[TBL] [Abstract][Full Text] [Related]
6. BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.
Zhou D; Li Z; Bai X
Med Sci Monit; 2017 Nov; 23():5321-5329. PubMed ID: 29117154
[TBL] [Abstract][Full Text] [Related]
7. Platelet derived growth factor receptor alpha mediates nodal metastases in papillary thyroid cancer by driving the epithelial-mesenchymal transition.
Ekpe-Adewuyi E; Lopez-Campistrous A; Tang X; Brindley DN; McMullen TP
Oncotarget; 2016 Dec; 7(50):83684-83700. PubMed ID: 27845909
[TBL] [Abstract][Full Text] [Related]
8. Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC.
Kim YR; Byun HS; Won M; Park KA; Kim JM; Choi BL; Lee H; Hong JH; Park J; Seok JH; Kim DW; Shong M; Park SK; Hur GM
BMC Cancer; 2008 May; 8():144. PubMed ID: 18498667
[TBL] [Abstract][Full Text] [Related]
9. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.
Gao SP; Mark KG; Leslie K; Pao W; Motoi N; Gerald WL; Travis WD; Bornmann W; Veach D; Clarkson B; Bromberg JF
J Clin Invest; 2007 Dec; 117(12):3846-56. PubMed ID: 18060032
[TBL] [Abstract][Full Text] [Related]
11. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
[TBL] [Abstract][Full Text] [Related]
12. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.
Zhang GQ; Jiao Q; Shen CT; Song HJ; Zhang HZ; Qiu ZL; Luo QY
Cancer Sci; 2021 Mar; 112(3):997-1010. PubMed ID: 33247999
[TBL] [Abstract][Full Text] [Related]
14. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
15. NADPH Oxidase NOX4 Is a Critical Mediator of BRAF
Azouzi N; Cailloux J; Cazarin JM; Knauf JA; Cracchiolo J; Al Ghuzlan A; Hartl D; Polak M; Carré A; El Mzibri M; Filali-Maltouf A; Al Bouzidi A; Schlumberger M; Fagin JA; Ameziane-El-Hassani R; Dupuy C
Antioxid Redox Signal; 2017 May; 26(15):864-877. PubMed ID: 27401113
[TBL] [Abstract][Full Text] [Related]
16. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells.
Arthan D; Hong SK; Park JI
Cancer Lett; 2010 Nov; 297(1):31-41. PubMed ID: 20570039
[TBL] [Abstract][Full Text] [Related]
17. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells.
Liu D; Liu Z; Condouris S; Xing M
J Clin Endocrinol Metab; 2007 Jun; 92(6):2264-71. PubMed ID: 17374713
[TBL] [Abstract][Full Text] [Related]
18. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
19. Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation.
Leslie K; Gao SP; Berishaj M; Podsypanina K; Ho H; Ivashkiv L; Bromberg J
Breast Cancer Res; 2010; 12(5):R80. PubMed ID: 20929542
[TBL] [Abstract][Full Text] [Related]
20. AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.
Couto JP; Almeida A; Daly L; Sobrinho-Simões M; Bromberg JF; Soares P
PLoS One; 2012; 7(10):e46869. PubMed ID: 23056499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
